Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Conditions: official terms
Carcinoma - Carcinoma, Squamous Cell - Head and Neck Neoplasms
Conditions: Keywords
Re-irradiation with Fractionated Stereotactic Radiosurgery for Head and Neck
Study Type
Study Phase
Phase 2
Study Design
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: Cetuximab and stereotactic radiosurgery
Type: Other
Overall Status
The primary objectives of this study are to determine the 1-year progression-free survival (PFS) of previously irradiated patients with squamous cell carcinoma of the head and neck (SCCHN) treated with radiosurgery and cetuximab and to evaluate the acute and late toxicities associated with the above therapy.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Histologically proven recurrent squamous cell carcinoma of the head and neck (SCCHN), who has received prior radiotherapy with or without chemotherapy. New primary is allowed if location is in a previously irradiated field. Biopsy is recommended for each recurrence; but is not mandated per study. This will be at the discretion of the principal investigator.

- Prior radiation dose of at least 60 Gy.

- Disease confined to locoregional site and can be encompassed in a stereotactic radiosurgery "portal"

- Tumor must be deemed to be inoperable or unresectable either by clinical or radiographic criteria. These criteria include encasement of great vessels, vertebral invasion or undue peri-operative risk.

- Prior surgery for recurrent or new SCCHN is allowed in previously irradiated patients. A minimum of 4 weeks should elapse between any surgery and treatment on study. However, high risk pathologic features should be present, such as positive margins, positive lymphadenopathy, perineural or angiolymphatic invasion. Measurable disease must be present for assessment of response.

- Karnofsky performance status > 60 (ECOG 0-2)

- Prior treatment with an EGFR Inhibitor is allowed if it was a part of prior curative therapy and was completed at least 30 days prior to commencement of study therapy

- Any number of prior chemotherapy regimens are allowed

- Measurable disease on imaging studies (MRI, CT, PET-CT or physical exam)

- Age > 18

- Estimated life expectancy > 12 weeks

- No prior radiation therapy or chemotherapy within 1 month of study enrollment

- No prior chemotherapy or targeted therapy within the previous 4 weeks

- ANC > 1000, PLT>75,000, Serum creatinine<2.5 mg/dL, Bilirubin <1.5 x upper limits of normal (ULN)

- Diabetes must be controlled prior to PET-CT scanning (blood glucose <200 mg/dL)

- Ability to provide written informed consent

Exclusion Criteria:

- Evidence of distant metastasis on upright chest x-ray (CXR), computed tomography (CT) or other staging studies

- History of any cancer other than SCCHN (except non-melanoma skin cancer or carcinoma in situ of the cervix) within the last 5 years.

- Patients in their reproductive age group should use an effective method of birth control. Patients who are breast-feeding, or have a positive pregnancy test will be excluded from the study

- Any co-morbidity or condition of sufficient severity to limit full compliance with the protocol per assessment by the investigator

- Concurrent serious infection

- History of known hypersensitivity to cetuximab or similar agents
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States
Status: Recruiting
Contact: Dwight Heron, MD - 412-641-4600 -
Start Date
July 2007
Completion Date
December 2014
University of Pittsburgh
University of Pittsburgh
Record processing date processed this data on July 28, 2015 page